Cyplasin Biomedical Ltd. (OTC: CPBM) Gains 250% in the Last Three Trading Sessions

(January 18, 2011) Shares of Cyplasin Biomedical Ltd., a Canada-based company, soared in trading on Tuesday, ending the day 55.56% higher at $0.140.

In the last three trading sessions, the Cyplasin Biomedical stock has gained a spectacular 250%.

Last week, Cyplasin Biomedical provided a corporate update for the year 2010. The company said that during 2010 it secured a worldwide, exclusive license for a platform vaccine technology from the National Institutes of Health. The company said that before it secured the license, the licensed platform technology received a total of $10 million in investment.

Cyplasin Biomedical also said that during 2010 it saw the development of a parallel revenue generation strategy within the $2 billion per year therapeutic Hepatitis C drug market.

In 2010, Cyplasin Biomedical also entered into a letter of agreement with Minapharm Pharma for the possible co-product development and distribution of products.

During 2010, Cyplasin Biomedical also identified a cGMP manufacturer for the active pharmaceutical ingredient of the C-Virin product and initiated purchase orders from them. The company also negotiated the final terms with a formulation specialty company to make a C-Virin product line.

About Cyplasin Biomedical Ltd.: Cyplasin Biomedical Ltd. is a specialty pharmaceutical company. The company is headquartered in Edmonton, Alberta, Canada.

• The Cyplasin Biomedical stock has a 52-week range of $0.03-$0.60.
• The stock trades on a daily average volume of 82,929.
• The stock is currently trading above its 50-day and below its 200-day moving average.
• The stock’s MACD has crossed the signal line on the upside, which is a bullish signal.

Summary

Cyplasin Biomedical made steady progress during 2010. The company’s shares have picked up strong momentum in the last three trading sessions.